Given that RGC rescue strategies may increase the optic nerve neuronal activity that induces OPG growth [88,89] and that some of the gene therapies are based on the deletion of an anti-tumor gene (e.g., PTEN) [126,127], the careful optimization of the treatment regimen (e.g., dose, sequence, cell-specificity, and timing) will be required for the translational study. The gene discussed is PTEN; the disease is neoplasm.